Literature DB >> 16103142

Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.

Mattias N E Forsell1, Yuxing Li, Maria Sundbäck, Krisha Svehla, Peter Liljeström, John R Mascola, Richard Wyatt, Gunilla B Karlsson Hedestam.   

Abstract

The current lack of envelope glycoprotein immunogens that elicit broadly neutralizing antibody responses remains a major challenge for human immunodeficiency virus type 1 (HIV-1) vaccine development. However, the recent design and construction of stable soluble gp140 trimers have shown that some neutralization breadth can be achieved by using immunogens that better mimic the functional viral spike complex. The use of genetic delivery systems to drive the in vivo expression of such immunogens for the stimulation of neutralizing antibodies against HIV-1 may offer advantages by maintaining the quaternary structure of the trimeric envelope glycoproteins. Here, we describe the biochemical and immunogenic properties of soluble HIV-1 envelope glycoprotein trimers expressed by recombinant Semliki Forest virus (rSFV). The results presented here demonstrate that rSFV supports the expression of stable soluble gp140 trimers that retain recognition by conformationally sensitive antibodies. Further, we show that rSFV particle immunizations efficiently primed immune responses as measured after a single boost with purified trimeric gp140 protein, resulting in a Th1-biased antibody response. This differed from the Th2-biased antibody response obtained after repeated immunizations with purified gp140 protein trimers. Despite this difference, both regimens stimulated neutralizing antibody responses of similar potency. This suggests that rSFV may be a useful component of a viral vector prime-protein boost regimen aimed at stimulating both cell-mediated immune responses and neutralizing antibodies against HIV-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103142      PMCID: PMC1193613          DOI: 10.1128/JVI.79.17.10902-10914.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Authors:  J R Mascola; M K Louder; T C VanCott; C V Sapan; J S Lambert; L R Muenz; B Bunow; D L Birx; M L Robb
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  X Yang; M Farzan; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

4.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

5.  A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.

Authors:  J M Binley; R W Sanders; B Clas; N Schuelke; A Master; Y Guo; F Kajumo; D J Anselma; P J Maddon; W C Olson; J P Moore
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

7.  High-level expression of G protein-coupled receptors with the aid of the Semliki Forest virus expression system.

Authors:  K Lundstrom; A Mills; E Allet; K Ceszkowski; G Agudo; A Chollet; P Liljestrom
Journal:  J Recept Signal Transduct Res       Date:  1995 Jan-Mar       Impact factor: 2.092

8.  Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.

Authors:  D Brand; F Lemiale; G Thibault; B Verrier; S Lebigot; P Roingeard; L Buzelay; S Brunet; F Barin
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

9.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Authors:  S P Mossman; F Bex; P Berglund; J Arthos; S P O'Neil; D Riley; D H Maul; C Bruck; P Momin; A Burny; P N Fultz; J I Mullins; P Liljeström; E A Hoover
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  High-level expression of the human neurokinin-1 receptor in mammalian cell lines using the Semliki Forest virus expression system.

Authors:  K Lundström; A Mills; G Buell; E Allet; N Adami; P Liljeström
Journal:  Eur J Biochem       Date:  1994-09-15
View more
  18 in total

1.  Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.

Authors:  Asa S Hidmark; Eva K L Nordström; Pia Dosenovic; Mattias N E Forsell; Peter Liljeström; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers.

Authors:  Javier Guenaga; Viktoriya Dubrovskaya; Natalia de Val; Shailendra K Sharma; Barbara Carrette; Andrew B Ward; Richard T Wyatt
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

4.  Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Authors:  Sunil K Khattar; Sweety Samal; Anthony L Devico; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Identification of cross-contaminated animal cells by PCR and isoenzyme analysis.

Authors:  R Ramya; T Nagarajan; V Sivakumar; R L Senthilkumar; B Bala Obulapathi; D Thiagarajan; V A Srinivasan
Journal:  Cytotechnology       Date:  2010-02-04       Impact factor: 2.058

6.  Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.

Authors:  Sunil K Khattar; Anthony L DeVico; Celia C LaBranche; Aruna Panda; David C Montefiori; Siba K Samal
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Authors:  Andreas Mörner; Iyadh Douagi; Mattias N E Forsell; Christopher Sundling; Pia Dosenovic; Sijy O'Dell; Barna Dey; Peter D Kwong; Gerald Voss; Rigmor Thorstensson; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2008-11-12       Impact factor: 5.103

Review 8.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.

Authors:  Steven W de Taeye; John P Moore; Rogier W Sanders
Journal:  Trends Immunol       Date:  2016-02-09       Impact factor: 16.687

9.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Authors:  Rogier W Sanders; Marit J van Gils; Ronald Derking; Devin Sok; Thomas J Ketas; Judith A Burger; Gabriel Ozorowski; Albert Cupo; Cassandra Simonich; Leslie Goo; Heather Arendt; Helen J Kim; Jeong Hyun Lee; Pavel Pugach; Melissa Williams; Gargi Debnath; Brian Moldt; Mariëlle J van Breemen; Gözde Isik; Max Medina-Ramírez; Jaap Willem Back; Wayne C Koff; Jean-Philippe Julien; Eva G Rakasz; Michael S Seaman; Miklos Guttman; Kelly K Lee; Per Johan Klasse; Celia LaBranche; William R Schief; Ian A Wilson; Julie Overbaugh; Dennis R Burton; Andrew B Ward; David C Montefiori; Hansi Dean; John P Moore
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

Review 10.  Neutralizing antibodies to HIV-1 induced by immunization.

Authors:  Laura E McCoy; Robin A Weiss
Journal:  J Exp Med       Date:  2013-02-11       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.